ESR1 and breast carcinoma: That it might also apply to triple-negative and HER2 breast cancer seems likely, considering that the single-cell atlas used for mapping of the cell lines with iCAF and myCAF clusters was generated as a composite of luminal ER+, HER2 and triple-negative breast cancers [17], but this awaits further scrutiny.